What is InspireMD, Inc.'s earnings per share (EPS)?

InspireMD, Inc. (NSPR) reported diluted earnings per share of -$0.76 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

InspireMD, Inc. (NSPR) Financials

NSPR

Trailing 12 months to June 30, 2026

Revenue $10.8M +53.4% YoY

Net Income -$52.5M -26.8% YoY

EPS (Diluted) -$0.62 YoY not available

Free Cash Flow -$42.5M -35.9% YoY

Market Cap $21.9M as of Oct 15, 2026

Price / Sales 2.0x on $10.8M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.7x on $31.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NSPR SEC filings page.

InspireMD, Inc. (NSPR) reported $10.8M in revenue over the twelve months to Jun 30, 2026, up 53.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NSPR FY2025 2026-10-04

InspireMD remains a development-stage business: revenue is expanding, but rising R&D and overhead are widening cash losses.

Gross economics improved unevenly: gross margin reached 29.5% in FY2025, yet operating margin deteriorated to -552.6% as spending grew faster than sales. That combination indicates the business is still absorbing development and administrative costs rather than converting product-level margin into operating earnings.

FY2025 revenue was $9.0M, while R&D reached $15.0M; product development therefore consumed more than reported sales, consistent with a company investing ahead of commercial scale. Operating cash flow was negative $35.1M, showing that the accounting loss translated into a substantial cash requirement.

External financing remains central to the funding model: FY2025 financing cash flow of $55.6M exceeded the year's operating cash outflow, while free cash flow was negative $36.8M. The reported liquidity comparison equaled 18.5 months of the latest annual operating outflow, so the balance sheet was being supported by financing activity rather than internally generated cash.

Financial Health Signals

Financial Health Score 49/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of InspireMD, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

InspireMD, Inc. held $54.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $35.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and InspireMD, Inc. scores 44/100 among other emerging companies.

Dilution

InspireMD, Inc. had 47M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and InspireMD, Inc. scores 22/100 among other emerging companies.

R&D Intensity

InspireMD, Inc. spent $15.0M on research and development in fiscal year 2025, which was 25.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and InspireMD, Inc. scores 58/100 among other emerging companies.

Revenue Progress

InspireMD, Inc. reported revenue of $9.0M in fiscal year 2025, against $7.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and InspireMD, Inc. scores 65/100 among other emerging companies.

Burn Trend

InspireMD, Inc.'s operations used $35.1M of cash in fiscal year 2025, against $21.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and InspireMD, Inc. scores 17/100 among other emerging companies.

Balance Sheet

InspireMD, Inc.'s cash, cash equivalents and investments came to $54.2M at the end of fiscal year 2025, against $14.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and InspireMD, Inc. scores 86/100 among other emerging companies.

Altman Z-Score Distress

-6.52

InspireMD, Inc. scores -6.52, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($21.9M) relative to total liabilities ($14.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

InspireMD, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

InspireMD, Inc. reported a net loss of $48.8M while operations used $35.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.8M

YoY-0.4%

QoQ-47.9%

5Y CAGR+11.3%

10Y CAGR+12.6%

InspireMD, Inc. generated $1.8M in revenue in Q2 2026. This represents a decrease of 0.4% from the same quarter a year earlier. Against the prior quarter it is down 47.9%.

EBITDA

-$14.3M

YoY-10.6%

QoQ-3.3%

InspireMD, Inc.'s EBITDA was -$14.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.6% from the same quarter a year earlier. Against the prior quarter it is down 3.3%.

Net Income

-$14.3M

YoY-8.9%

QoQ-4.6%

InspireMD, Inc. reported -$14.3M in net income in Q2 2026. This represents a decrease of 8.9% from the same quarter a year earlier. Against the prior quarter it is down 4.6%.

EPS (Diluted)

-$0.17

QoQ-6.3%

InspireMD, Inc. earned -$0.17 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 6.3%.

Cash & Balance Sheet

Free Cash Flow

-$11.2M

YoY-26.0%

QoQ+10.4%

InspireMD, Inc. recorded an outflow of $11.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 26.0% from the same quarter a year earlier. Against the prior quarter it is up 10.4%.

Cash & Debt

$15.1M

YoY+31.6%

QoQ+33.3%

5Y CAGR-18.2%

10Y CAGR+32.8%

InspireMD, Inc. held $15.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

46M

QoQ-0.7%

5Y CAGR+42.5%

10Y CAGR+4.5%

InspireMD, Inc. had 46M shares outstanding in Q2 2026. Against the prior quarter it is down 0.7%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

-43.7%

YoY-61.3pp

QoQ-63.9pp

5Y change-68.9pp

10Y change-55.2pp

InspireMD, Inc.'s gross margin was -43.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 61.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 63.9 percentage points.

Return on Equity

-45.5%

YoY+19.5pp

QoQ-14.1pp

5Y change-36.9pp

InspireMD, Inc.'s ROE was -45.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 19.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.1 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$4.3M

YoY+12.0%

QoQ-9.8%

5Y CAGR+27.2%

10Y CAGR+31.5%

InspireMD, Inc. invested $4.3M in research and development in Q2 2026. This represents an increase of 12.0% from the same quarter a year earlier. Against the prior quarter it is down 9.8%.

Capital Expenditures

$330K

YoY-42.7%

QoQ+70.1%

5Y CAGR+43.6%

InspireMD, Inc. invested $330K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 42.7% from the same quarter a year earlier. Against the prior quarter it is up 70.1%.

Share Buybacks

Not reported for Q2 2026.

NSPR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NSPR quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$10.8M	$9.0M+28.1%	$7.0M+13.0%	$6.2M+20.0%	$5.2M+15.0%	$4.5M+80.9%	$2.5M-33.2%	$3.7M+3.3%	$3.6M+30.4%	$2.8M+45.8%	$1.9M-18.0%	$2.3M-18.0%	$2.8M-42.2%	$4.9M-8.9%	$5.3M-10.9%	$6.0M
Cost of Revenue	$8.9M	$6.3M+15.0%	$5.5M+25.1%	$4.4M+8.5%	$4.1M+8.4%	$3.7M+55.7%	$2.4M-19.0%	$3.0M+13.8%	$2.6M+19.8%	$2.2M+21.4%	$1.8M-31.2%	$2.6M+28.1%	$2.0M-10.9%	$2.3M-19.9%	$2.8M-5.4%	$3.0M
Gross Profit	$2.0M	$2.6M+75.9%	$1.5M-16.7%	$1.8M+61.8%	$1.1M+48.1%	$754K+808.4%	$83K-89.0%	$756K-24.0%	$995K+70.1%	$585K+473.5%	$102K+134.5%	-$296K-137.8%	$784K-69.7%	$2.6M+3.6%	$2.5M-16.5%	$3.0M
R&D Expenses	$16.2M	$15.0M+10.0%	$13.6M+70.8%	$8.0M+2.2%	$7.8M+51.4%	$5.2M+131.0%	$2.2M-24.4%	$3.0M+92.4%	$1.5M+20.3%	$1.3M-1.2%	$1.3M-64.6%	$3.6M-58.3%	$8.7M+110.4%	$4.2M+4.2%	$4.0M+61.2%	$2.5M
SG&A Expenses	$19.3M	$20.7M+35.3%	$15.3M+37.8%	$11.1M+32.9%	$8.4M+12.8%	$7.4M+20.9%	$6.1M+17.3%	$5.2M+8.1%	$4.8M-6.8%	$5.2M+3.7%	$5.0M-21.7%	$6.4M-30.0%	$9.1M+1.7%	$9.0M-35.4%	$13.9M+13.1%	$12.3M
Operating Income	-$53.6M	-$49.6M-48.1%	-$33.5M-58.5%	-$21.1M-13.0%	-$18.7M-27.2%	-$14.7M-41.8%	-$10.4M-5.7%	-$9.8M-29.0%	-$7.6M+7.5%	-$8.2M-7.6%	-$7.6M+47.2%	-$14.5M+38.9%	-$23.7M-57.2%	-$15.1M+14.1%	-$17.5M-27.8%	-$13.7M
EBITDA	N/A	N/A	N/A	$210.9M	N/A	-$14.6M-42.3%	-$10.2M-5.9%	-$9.7M-29.3%	-$7.5M+7.5%	-$8.1M-7.6%	-$7.5M+47.6%	-$14.3M+38.8%	-$23.4M-57.7%	-$14.9M+14.7%	-$17.4M-27.7%	-$13.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$119K-83.5%	$721K-30.4%	$1.0M-26.5%	$1.4M-67.0%	$4.3M+244.7%	$1.2M+69.6%	$730K
Income Tax	N/A	$63K+6.8%	$59K-9.2%	$65K+132.1%	$28K-37.8%	$45K+1025.0%	$4K-83.3%	$24K	N/A	$27K+2600.0%	$1K-75.0%	$4K-66.7%	$12K+50.0%	$8K-42.9%	$14K+600.0%	$2K
Net Income	-$52.5M	-$48.8M-52.4%	-$32.0M-60.7%	-$19.9M-7.7%	-$18.5M-24.0%	-$14.9M-41.5%	-$10.5M-5.0%	-$10.0M-38.7%	-$7.2M+14.2%	-$8.4M+0.3%	-$8.5M+45.7%	-$15.6M+37.9%	-$25.1M+14.2%	-$29.3M-66.3%	-$17.6M-20.0%	-$14.7M
EPS (Basic)	N/A	-$0.760.0%	-$0.76+7.3%	-$0.82+65.1%	-$2.35-15.8%	-$2.03	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.62	-$0.76	-$0.76	-$0.82	-$2.35	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	64M	42M	24M	8M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.8M-0.4%	$3.4M+122.2%	$3.1M+61.6%	$2.5M+39.4%	$1.8M+2.2%	$1.5M+1.2%	$1.9M+10.7%	$1.8M+16.3%
Cost of Revenue	$2.5M+73.7%	$2.7M+119.2%	$2.0M+33.0%	$1.7M+18.8%	$1.5M+4.0%	$1.2M+1.5%	$1.5M+17.8%	$1.4M+24.9%
Gross Profit	-$774K-347.3%	$687K+135.3%	$1.2M+151.6%	$864K+108.7%	$313K-5.4%	$292K0.0%	$469K-7.1%	$414K-5.5%
R&D Expenses	$4.3M+12.0%	$4.8M+17.3%	$3.5M-5.9%	$3.6M-7.2%	$3.8M+12.7%	$4.1M+54.6%	$3.7M+81.5%	$3.9M+85.5%
SG&A Expenses	$4.2M-22.0%	$4.7M-4.5%	$4.5M+7.6%	$5.9M+68.8%	$5.3M+42.2%	$4.9M+28.6%	$4.2M+42.4%	$3.5M+12.9%
Operating Income	-$14.4M-11.0%	-$14.0M-22.0%	-$12.1M-29.0%	-$13.1M-54.2%	-$13.0M-57.6%	-$11.5M-54.6%	-$9.4M-61.3%	-$8.5M-50.1%
EBITDA	-$14.3M-10.6%	-$13.8M-21.7%	N/A	-$12.9M-54.0%	-$12.9M-57.6%	-$11.4M-54.7%	N/A	-$8.4M-50.4%
Net Income	-$14.3M-8.9%	-$13.7M-22.6%	-$11.8M-28.2%	-$12.7M-61.1%	-$13.2M-66.3%	-$11.2M-58.8%	-$9.2M-69.7%	-$7.9M-52.4%
EPS (Basic)	-$0.17+34.6%	-$0.16-172.7%	-$0.12+33.3%	-$0.17-6.3%	-$0.26-18.2%	$0.22+204.8%	-$0.18-38.5%	-$0.16-6.7%
EPS (Diluted)	-$0.17	-$0.16-172.7%	-$0.12	-$0.17	-$0.26-18.2%	$0.22+204.8%	-$0.18-38.5%	-$0.16-6.7%
Diluted Shares (Avg)	85M	84M+67.6%	N/A	73M	51M+42.2%	50M+46.0%	N/A	48M+42.3%

Not reported in any period shown, so not listed: Interest Expense, Income Tax.

NSPR Balance Sheet

NSPR quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$69.4M+48.3%	$46.8M-1.8%	$47.6M+93.3%	$24.7M-37.9%	$39.7M+123.4%	$17.8M+79.9%	$9.9M-19.6%	$12.3M+101.2%	$6.1M-35.1%	$9.4M+65.3%	$5.7M-50.3%	$11.5M-44.8%	$20.7M+29.5%	$16.0M+53.0%	$10.5M
Current Assets	$61.5M+51.7%	$40.5M-8.2%	$44.2M+107.1%	$21.3M-42.5%	$37.1M+141.8%	$15.3M+96.4%	$7.8M-31.6%	$11.4M+121.5%	$5.2M-40.3%	$8.6M+86.4%	$4.6M-50.6%	$9.4M-50.4%	$18.9M+32.1%	$14.3M+45.6%	$9.8M
Cash & Equivalents	$8.9M-52.7%	$18.9M+96.2%	$9.6M+108.1%	$4.6M-61.4%	$12.0M-5.1%	$12.6M+129.3%	$5.5M-41.2%	$9.4M+152.9%	$3.7M-50.6%	$7.5M+130.8%	$3.3M-48.3%	$6.3M-57.5%	$14.8M+44.1%	$10.3M+101.9%	$5.1M
Short-Term Investments	$45.3M+188.0%	$15.7M-46.5%	$29.4M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.4M+32.1%	$2.6M+22.0%	$2.1M+29.9%	$1.6M+41.8%	$1.1M-19.2%	$1.4M+14.5%	$1.2M+9.0%	$1.1M+112.8%	$533K+6.6%	$500K-33.6%	$753K-60.9%	$1.9M+20.8%	$1.6M-8.7%	$1.7M-15.4%	$2.1M
Accounts Receivable	$2.2M+37.9%	$1.6M-12.9%	$1.8M+74.5%	$1.0M-15.5%	$1.2M+157.1%	$476K-42.2%	$823K+14.9%	$716K+11.4%	$643K+80.6%	$356K-12.1%	$405K-36.2%	$635K-63.5%	$1.7M-4.7%	$1.8M-20.1%	$2.3M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$14.2M+32.5%	$10.7M+31.7%	$8.1M+12.1%	$7.3M+17.5%	$6.2M+10.1%	$5.6M+24.8%	$4.5M+27.6%	$3.5M+13.5%	$3.1M-42.1%	$5.4M-37.9%	$8.6M-39.4%	$14.2M+206.8%	$4.6M-56.3%	$10.6M+186.4%	$3.7M
Current Liabilities	$10.7M+39.5%	$7.7M+27.5%	$6.0M+18.7%	$5.1M+16.6%	$4.3M+17.3%	$3.7M+18.9%	$3.1M+6.7%	$2.9M+17.6%	$2.5M-48.1%	$4.8M-30.1%	$6.8M-19.3%	$8.5M+109.6%	$4.0M+13.9%	$3.5M+3.2%	$3.4M
Non-Current Liabilities	$3.5M+14.7%	$3.0M+43.4%	$2.1M-3.1%	$2.2M+19.5%	$1.8M-4.0%	$1.9M+38.1%	$1.4M+128.4%	$605K-3.0%	$624K+6.3%	$587K-67.5%	$1.8M-68.7%	$5.8M+862.2%	$600K-91.5%	$7.1M+2521.5%	$270K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.1M-78.4%	$5.1M	N/A	N/A	N/A
Total Equity	$55.2M+53.0%	$36.1M-8.6%	$39.5M+127.1%	$17.4M-48.1%	$33.5M+175.7%	$12.2M+126.0%	$5.4M-38.6%	$8.8M+221.3%	$2.7M-32.6%	$4.0M+237.3%	-$2.9M-5.7%	-$2.8M-117.3%	$16.1M+199.0%	$5.4M-20.3%	$6.8M
Retained Earnings	-$302.3M-19.2%	-$253.5M-14.4%	-$221.5M-9.9%	-$201.6M-10.1%	-$183.1M-8.9%	-$168.2M-6.7%	-$157.6M-6.8%	-$147.6M-5.2%	-$140.4M-6.4%	-$131.9M-7.3%	-$123.0M-14.5%	-$107.4M-47.2%	-$73.0M-66.9%	-$43.7M-19.3%	-$36.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$44.6M+33.9%	$56.5M+46.0%	$69.4M+48.3%	$78.5M+55.4%	$33.3M-40.1%	$38.7M-8.0%	$46.8M-1.8%	$50.5M+0.9%
Current Assets	$36.6M+43.8%	$48.6M+51.2%	$61.5M+51.7%	$70.4M+51.7%	$25.5M-50.9%	$32.1M-16.5%	$40.5M-8.2%	$46.4M-0.7%
Cash & Equivalents	$15.1M+31.6%	$11.4M-8.2%	$8.9M-52.7%	$63.4M+300.8%	$11.5M-59.5%	$12.4M+31.9%	$18.9M+96.2%	$15.8M+14.3%
Short-Term Investments	$15.3M+94.2%	$30.2M+120.4%	$45.3M+188.0%	$0-100.0%	$7.9M-58.1%	$13.7M-44.2%	$15.7M-46.5%	$24.6M-15.7%
Inventory	$2.7M-11.6%	$3.0M+7.6%	$3.4M+32.1%	$3.6M+47.5%	$3.1M+38.4%	$2.8M+19.6%	$2.6M+22.0%	$2.4M+32.4%
Accounts Receivable	$1.8M+14.1%	$2.4M+50.7%	$2.2M+37.9%	$2.0M+28.2%	$1.6M+21.8%	$1.6M+33.1%	$1.6M-12.9%	$1.5M+46.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$13.1M+0.2%	$12.9M+24.5%	$14.2M+32.5%	$14.4M+57.3%	$13.1M+47.2%	$10.3M+48.8%	$10.7M+31.7%	$9.1M+35.0%
Current Liabilities	$9.6M+6.4%	$9.4M+28.2%	$10.7M+39.5%	$10.8M+48.9%	$9.1M+30.2%	$7.4M+51.1%	$7.7M+27.5%	$7.3M+54.9%
Non-Current Liabilities	$3.5M-13.6%	$3.4M+15.2%	$3.5M+14.7%	$3.5M+89.9%	$4.0M+108.8%	$3.0M+43.4%	$3.0M+43.4%	$1.9M-10.0%
Total Equity	$31.5M+55.7%	$43.6M+53.9%	$55.2M+53.0%	$64.1M+55.0%	$20.2M-56.7%	$28.3M-19.2%	$36.1M-8.6%	$41.4M-4.4%
Retained Earnings	-$330.3M-18.9%	-$316.0M-19.4%	-$302.3M-19.2%	-$290.5M-18.9%	-$277.8M-17.5%	-$264.7M-15.8%	-$253.5M-14.4%	-$244.3M-13.1%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

NSPR Cash Flow Statement

NSPR quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$41.2M	-$35.1M-60.5%	-$21.9M-33.5%	-$16.4M-5.4%	-$15.5M-17.7%	-$13.2M-45.5%	-$9.1M+7.4%	-$9.8M-29.0%	-$7.6M+6.5%	-$8.1M-8.5%	-$7.5M+35.4%	-$11.6M+40.1%	-$19.4M-88.0%	-$10.3M-20.0%	-$8.6M-42.9%	-$6.0M
Depreciation & Amortization	N/A	N/A	N/A	$232.0M	N/A	$161K+6.6%	$151K-4.4%	$158K+13.7%	$139K-9.2%	$153K+7.7%	$142K-6.6%	$152K-42.2%	$263K+26.4%	$208K+73.3%	$120K+34.8%	$89K
Stock-Based Compensation	N/A	$12.3M+21.6%	$10.1M+125.8%	$4.5M+90.9%	$2.4M+49.2%	$1.6M+160.1%	$606K+86.5%	$325K+364.3%	$70K-89.6%	$672K-31.3%	$978K-68.5%	$3.1M-24.9%	$4.1M+7.8%	$3.8M-63.6%	$10.6M+10.1%	$9.6M
Capital Expenditures	$1.3M	$1.7M+18.5%	$1.4M+268.0%	$381K-19.5%	$473K+37.5%	$344K+290.9%	$88K-69.0%	$284K+323.9%	$67K-74.0%	$258K+426.5%	$49K+206.3%	$16K-88.0%	$133K-34.2%	$202K-30.3%	$290K+108.6%	$139K
Free Cash Flow	-$42.5M	-$36.8M-58.0%	-$23.3M-38.9%	-$16.8M-4.6%	-$16.0M-18.2%	-$13.6M-47.8%	-$9.2M+9.2%	-$10.1M-31.6%	-$7.7M+8.5%	-$8.4M-11.2%	-$7.5M+35.0%	-$11.6M+40.4%	-$19.5M-85.6%	-$10.5M-18.4%	-$8.9M-44.4%	-$6.1M
Investing Cash Flow	-$8.2M	-$30.6M-341.8%	$12.6M+178.6%	-$16.1M-290.6%	$8.4M+137.6%	-$22.5M-11909.1%	-$187K+51.7%	-$387K-779.5%	-$44K+86.2%	-$318K	N/A	N/A	N/A	-$376K-774.4%	-$43K-430.8%	$13K
Financing Cash Flow	N/A	$55.6M+201.2%	$18.5M-50.8%	$37.5M+26910.0%	-$140K-100.4%	$35.0M+113.7%	$16.4M+158.8%	$6.3M-52.6%	$13.4M+188.6%	$4.6M	N/A	N/A	N/A	$15.1M+36.7%	$11.1M+3.7%	$10.7M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$21K	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$10.9M-30.7%	-$12.3M-40.3%	-$9.3M-38.4%	-$8.6M-51.5%	-$8.3M-91.4%	-$8.8M-73.6%	-$6.8M-61.6%	-$5.7M-41.0%
Depreciation & Amortization	$158K+47.7%	$149K+52.0%	N/A	$128K+82.9%	$107K+62.1%	$98K+42.0%	N/A	$70K+20.7%
Stock-Based Compensation	N/A	$2.1M-22.9%	N/A	N/A	N/A	$2.7M+4.2%	N/A	N/A
Capital Expenditures	$330K-42.7%	$194K-46.0%	$398K+28.0%	$329K-21.9%	$576K+21.3%	$359K+84.1%	$311K+44.7%	$421K+338.5%
Free Cash Flow	-$11.2M-26.0%	-$12.5M-36.9%	-$9.7M-38.0%	-$9.0M-46.4%	-$8.9M-84.5%	-$9.2M-74.0%	-$7.1M-60.8%	-$6.1M-47.9%
Investing Cash Flow	$14.7M+175.3%	$14.8M+768.3%	-$45.1M-647.6%	$7.6M+227.5%	$5.3M-3.3%	$1.7M-64.7%	$8.2M+22994.4%	-$5.9M-192.8%
Financing Cash Flow	N/A	N/A	$0-100.0%	$52.9M+5584.6%	$2.1M	$506K	$1.6M	-$965K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NSPR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NSPR quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	29.5%+8.0pp	21.5%-7.6pp	29.1%+7.5pp	21.6%+4.8pp	16.8%+13.4pp	3.3%-17.0pp	20.3%-7.3pp	27.6%+6.4pp	21.2%+15.8pp	5.4%+18.2pp	-12.8%-40.6pp	27.8%-25.3pp	53.1%+6.4pp	46.7%-3.1pp	49.9%
Operating Margin	-552.6%	-478.0%	-340.7%	-361.9%	-327.4%	-417.7%	-263.8%	-211.4%	-298.1%	-403.8%	-627.1%	-840.9%	-309.3%	-328.0%	-228.7%
Net Margin	-543.4%	-456.6%	-321.0%	-357.6%	-331.9%	-424.3%	-269.8%	-201.1%	-305.6%	-446.7%	-674.7%	-890.5%	-600.4%	-329.0%	-244.3%
Return on Equity	-88.4%+0.3pp	-88.7%-38.3pp	-50.4%+55.9pp	-106.3%-61.8pp	-44.5%+42.2pp	-86.7%+99.8pp	-186.5%-103.9pp	-82.6%+226.8pp	-309.4%-100.3pp	-209.2%	N/A	N/A	-181.7%+145.0pp	-326.7%-109.6pp	-217.1%
Return on Assets	-70.3%-1.9pp	-68.4%-26.6pp	-41.8%+33.2pp	-75.0%-37.4pp	-37.6%+21.7pp	-59.3%+42.3pp	-101.6%-42.7pp	-58.9%+79.3pp	-138.2%-48.3pp	-89.9%+183.8pp	-273.8%-54.8pp	-219.0%-78.0pp	-141.0%-31.2pp	-109.9%+30.2pp	-140.1%
Current Ratio	5.74+0.5x	5.28-2.1x	7.34+3.1x	4.21-4.3x	8.53+4.4x	4.14+1.6x	2.51-1.4x	3.91+1.8x	2.08+0.3x	1.81+1.1x	0.68-0.4x	1.11-3.6x	4.68+0.6x	4.03+1.2x	2.86
Debt-to-Equity	0.260.0x	0.30+0.1x	0.21-0.2x	0.42+0.2x	0.18-0.3x	0.46-0.4x	0.84+0.4x	0.40-0.7x	1.14-0.2x	1.33	N/A	N/A	0.29-1.7x	1.97+1.4x	0.55
Asset Turnover	0.130.0x	0.150.0x	0.13-0.1x	0.21+0.1x	0.110.0x	0.14-0.2x	0.38+0.1x	0.29-0.2x	0.45+0.3x	0.20-0.2x	0.41+0.2x	0.250.0x	0.23-0.1x	0.33-0.2x	0.57
FCF Margin	-409.5%	-332.0%	-270.1%	-309.7%	-301.5%	-369.0%	-271.3%	-213.1%	-303.8%	-398.3%	-502.7%	-691.8%	-215.5%	-165.8%	-102.3%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	-43.7%-61.3pp	20.2%+1.1pp	37.5%+13.4pp	34.2%+11.4pp	17.6%-1.4pp	19.1%-0.2pp	24.1%-4.6pp	22.9%-5.3pp
Operating Margin	-815.6%	-411.4%	-383.7%	-517.3%	-732.2%	-749.5%	-480.6%	-467.5%
Net Margin	-808.8%	-402.9%	-373.6%	-503.7%	-739.6%	-730.3%	-470.7%	-435.9%
Return on Equity	-45.5%+19.5pp	-31.4%+8.0pp	-21.3%+4.1pp	-19.8%-0.7pp	-65.0%-48.1pp	-39.4%-19.3pp	-25.4%-11.7pp	-19.1%-7.1pp
Return on Assets	-32.1%+7.3pp	-24.2%+4.6pp	-17.0%+2.6pp	-16.2%-0.6pp	-39.4%-25.2pp	-28.9%-12.1pp	-19.6%-8.3pp	-15.6%-5.3pp
Current Ratio	3.80+1.0x	5.15+0.8x	5.74+0.5x	6.51+0.1x	2.81-4.6x	4.36-3.5x	5.28-2.1x	6.39-3.6x
Debt-to-Equity	0.42-0.2x	0.29-0.1x	0.260.0x	0.220.0x	0.65+0.5x	0.36+0.2x	0.30+0.1x	0.22+0.1x
Asset Turnover	0.040.0x	0.060.0x	0.050.0x	0.030.0x	0.050.0x	0.040.0x	0.040.0x	0.040.0x
FCF Margin	-633.8%	-368.8%	-309.4%	-355.2%	-501.1%	-598.5%	-362.3%	-338.2%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
InspireMD, Inc. NSPR	FY2025	$9.0M	-$48.8M	N/A	$21.9M	49/100
Baird Medical Investment Holdings Ltd BDMD	FY2025	$22.5M	-$27.3M	N/A	$17.7M	26/100
Profound Medical Corp. PROF	FY2025	$16.1M	-$42.6M	N/A	$241.9M	55/100
Avita Medical, Inc. RCEL	FY2025	$71.6M	-$48.6M	-67.8%	$405.1M	45/100
Sera Prognostics, Inc. SERA	FY2025	$81K	-$31.9M	N/A	$81.7M	—

Where InspireMD, Inc. Ranks

Frequently Asked Questions

What is InspireMD, Inc.'s annual revenue?

InspireMD, Inc. (NSPR) reported $9.0M in total revenue for fiscal year 2025. This represents a 28.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is InspireMD, Inc.'s revenue growing?

InspireMD, Inc. (NSPR) revenue grew by 28.1% year-over-year, from $7.0M to $9.0M in fiscal year 2025.

Is InspireMD, Inc. profitable?

No, InspireMD, Inc. (NSPR) reported a net income of -$48.8M in fiscal year 2025.

What is InspireMD, Inc.'s gross margin?

InspireMD, Inc. (NSPR) had a gross margin of 29.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is InspireMD, Inc.'s return on equity (ROE)?

InspireMD, Inc. (NSPR) has a return on equity of -88.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is InspireMD, Inc.'s free cash flow?

InspireMD, Inc. (NSPR) recorded an outflow of $36.8M in free cash flow during fiscal year 2025. This represents a -58.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is InspireMD, Inc.'s operating cash flow?

InspireMD, Inc. (NSPR) recorded an outflow of $35.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are InspireMD, Inc.'s total assets?

InspireMD, Inc. (NSPR) had $69.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are InspireMD, Inc.'s capital expenditures?

InspireMD, Inc. (NSPR) invested $1.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does InspireMD, Inc. spend on research and development?

InspireMD, Inc. (NSPR) invested $15.0M in research and development during fiscal year 2025.

How many shares does InspireMD, Inc. have outstanding?

InspireMD, Inc. (NSPR) had 47M shares outstanding as of fiscal year 2025.

What is InspireMD, Inc.'s current ratio?

InspireMD, Inc. (NSPR) had a current ratio of 5.74 as of fiscal year 2025, which is generally considered healthy.

What is InspireMD, Inc.'s debt-to-equity ratio?

InspireMD, Inc. (NSPR) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is InspireMD, Inc.'s return on assets (ROA)?

InspireMD, Inc. (NSPR) had a return on assets of -70.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is InspireMD, Inc.'s P/E ratio?

InspireMD, Inc. (NSPR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $21.9M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is InspireMD, Inc.'s price-to-sales ratio?

InspireMD, Inc. (NSPR) trades at 2.0x sales, its market capitalization divided by revenue of $10.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $21.9M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does InspireMD, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, InspireMD, Inc. (NSPR) held $54.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $35.1M over that year. Dividing the one by the other, the reported balance equals about 19 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is InspireMD, Inc.'s Altman Z-Score?

InspireMD, Inc. (NSPR) has an Altman Z-Score of -6.52, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is InspireMD, Inc.'s Piotroski F-Score?

InspireMD, Inc. (NSPR) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are InspireMD, Inc.'s earnings high quality?

InspireMD, Inc. (NSPR) reported a net loss of $48.8M while operations used $35.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is InspireMD, Inc.?

InspireMD, Inc. (NSPR) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.